(P115) Breast Cancer Laterality Does Not Influence Overall Survival in a Large Modern Cohort: Implications for Radiation-Related Cardiac Mortality

Publication
Article
OncologyOncology Vol 28 No 1S
Volume 28
Issue 1S

Radiotherapy for left-sided breast cancer has historically been associated with an elevated risk of cardiac mortality, based upon studies in the era predating computed tomography (CT)-based treatment planning. This study assessed the impact of tumor laterality on overall survival (OS) in a large cohort treated with modern techniques to determine if left-sided treatment is still associated with a heightened risk of cardiac mortality.

P115: Figure

Charles E. Rutter, MD, Amy Moreno, Shane Lloyd, MD, Anees Chagpar, MD, Suzanne B. Evans, MD; Yale–New Haven Hospital

Objectives: Radiotherapy for left-sided breast cancer has historically been associated with an elevated risk of cardiac mortality, based upon studies in the era predating computed tomography (CT)-based treatment planning. This study assessed the impact of tumor laterality on overall survival (OS) in a large cohort treated with modern techniques to determine if left-sided treatment is still associated with a heightened risk of cardiac mortality.

Methods: Patients treated for breast cancer with breast-conserving surgery and adjuvant external beam radiotherapy were identified in National Cancer Database (NCDB), a prospectively maintained nationwide database. Overall survival (OS) was compared based upon tumor laterality using Kaplan-Meier analysis. Separate analyses were performed for patients with noninvasive and invasive carcinoma, as well as patients treated with breast-only radiotherapy and breast plus regional nodal radiotherapy. Multivariate Cox regression analysis of OS was performed with age, estrogen receptor status, American Joint Committee on Cancer (AJCC) stage group, tumor grade, Charlson/Deyo comorbidity score, adjuvant chemotherapy or endocrine therapy receipt, and tumor laterality as covariates.

Results: We identified 344,831 patients treated between 1998 and 2006 for noninvasive (12.1%) and invasive carcinoma (87.9%), with a median follow-up of 72.5 months (range: 0–170 mo) in the overall cohort. Clinical, tumor, and treatment characteristics of patients with left-sided cancers (50.7%) closely matched those of patients with right-sided cancers. Regional nodal radiation was employed in 14.2% of patients treated for invasive cancer. No difference in OS was noted when comparing patients by tumor laterality for patients treated with breast-only radiotherapy (hazard ratio [HR] = 0.984; 95% confidence interval [CI], 0.965–1.005; P = .132), as well as for invasive carcinoma treated with breast and regional nodal radiotherapy (HR = 1.001; 95% CI, 0.959–1.045; P = .957). In multivariate analysis including potential confounders of a potential OS-by-laterality effect, OS was identical between left- and right-sided cancers (Figure; HR = 1.002; 95% CI, 0.973–1.032; P = .874). When analyzing patients with at least 10 years of follow-up (n = 27,725), it remained that there was no significant difference in OS by laterality, both in patients treated with breast-only (HR = 0.955; 95% CI, 0.863–1.056; P = .368) and breast plus regional nodal radiotherapy (HR = 0.859; 95% CI, 0.668–1.080; P = .155).

Conclusions: Treatment of left-sided invasive and noninvasive breast cancer with radiotherapy does not appear to increase the risk of death in this large prospective national database relative to right-sided tumors. Consequently, radiotherapy delivered in a modern fashion using CT planning may not increase the risk of cardiac mortality.

Articles in this issue

(P113) Age and Marital Status Are Associated With Choice of Mastectomy in Patients Eligible for Breast Conservation Therapy
(P112) Single-Institution Experience With Intrabeam IORT for Treatment of Early-Stage Breast Cancer
(P110) Breast Cancer Before Age 40: Current Patterns in Clinical Presentation and Local Management
(P111) Accelerated Partial-Breast Irradiation With Multicatheter High-Dose-Rate Brachytherapy: Feasibility and Results in a Private Practice Cohort
(P115) Breast Cancer Laterality Does Not Influence Overall Survival in a Large Modern Cohort: Implications for Radiation-Related Cardiac Mortality
(P117) Anatomical Variations and Radiation Technique for Breast Cancer
(P116) Bilateral Immediate DIEP Reconstruction and Postmastectomy Radiotherapy: Experience at a Tertiary Care Institution
(P118) Metadherin Overexpression Is Associated With Improved Locoregional Control After Mastectomy
(P119) Effect of Economic Environment on Use of Postlumpectomy Radiation Therapy for Stage I Breast Cancer
(P120) Immediate Versus Delayed Reconstruction After Mastectomy in the United States Medicare Breast Cancer Patient
(P121) Trend in Age and Racial Disparities in the Receipt of Postlumpectomy Radiation Therapy for Stage I Breast Cancer: 2004–2009
(P122) Streamlining Referring Physicians Orders With ‘Reflex Testing’ Significantly Decreases Time to Resolution for Abnormal Screening Mammograms
(P123) National Trends in the Local Management of Early-Stage Paget Disease of the Breast
(P124) Effect of Inhomogeneity on Cardiac and Lung Dose in Partial-Breast Irradiation Using HDR Brachytherapy
(P125) Breast Cancer Outcomes With Anthracycline-Based Chemotherapy for Residual Disease Burden After Full-Dose Neoadjuvant Chemotherapy and Surgery Followed by Radiation Treatment
Recent Videos
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Related Content